Last updated on January 2017

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months


Brief description of study

This study is a multi-center, randomized, double-blind Phase III Clinical trial. The purpose of this study is to assess the immunogenicity and safety of the quadrivalent cell culture-derived influenza vaccine compare to the trivalent cell culture-derived influenza vaccine in children aged 6~35 months.

Detailed Study Description

Subjects are randomly assigned in a 2:1 ratio to NBP607-QIV 0.5mL versus NBP607-TIV 0.25mL. To assess the immunogenicity, antibody levels are evaluated by hemagglutination inhibition(HI) assay from sera obtained at pre-vaccination and 28 days post-vaccination. To assess the safety, solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination are assessed and reported. The serious adverse events are collected during 6 months post-vaccination.

Clinical Study Identifier: NCT03020628

Contact Investigators or Research Sites near you

Start Over

Dae Sun Jo

Chonbuk National University Hospital
Jeonju, Korea, Republic of
7.38miles
  Connect »